The description of Elagolix's MOO appears to indicate that the FDA review shouldn't affect Elagolix since it is the opposite of a GnRH agonist though it appears to produce the same end result. I think the initial spurt produced by an agonist is the problem but i'm a layman.
Yeah, I'm assuming the FDA review shouldn't have an impact on the elagolix program given what appears to be an entirely opposite MoA (antagonist vs. agonist), but I thought I would throw this out there given how material elagolix is to the NBIX story.
Market Data 
Markets 
AI
